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When a new antiepilepsy agent is being evaluated
it is critical, but not always feasible, to have access
to two different kinds of information. The ﬁrst is
efﬁcacy data from rigorous, prospective, random-
ized double-blind trials. The second is information
on the drug’s ‘‘effectiveness’’ in a large popula-
tion of patients, with a broad spectrum of seizure
types, who are treated in a more ‘‘real world’’ sit-
uation. With zonisamide, we are fortunate to have
an abundance of both kinds of information.
The data from the controlled clinical trials re-
ported by Drs. Faught and Brodie complement
those from pre- and postmarketing studies con-
ducted in Japan. On the one hand, clinicians can
be conﬁdent that zonisamide is safe and works well
in refractory partial seizures, as demonstrated in
US and European pivotal trials, and that its efﬁcacy
appears be similar to, if not better than, other new
antiepilepsy drugs (AEDs), such as gabapentin, lam-
otrigine, tiagabine, and topiramate, which have
been evaluated in the same way. Nevertheless clin-
icians may not be sure exactly where zonisamide
ﬁts into their clinical practice because it has been
tested in the type of patients dissimilar to the
patients they see every day. With access to data
on the use of zonisamide over a 10-year-period in
Japan, clinicians in the United States and Europe
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will have a head start on integrating this agent into
their AED armamentarium.
It is important to note that the US and Euro-
pean trials studied the use of zonisamide as ad-
junctive therapy. Japanese experience suggests
that this agent may, in fact, be better tolerated
and more effective as monotherapy. Thus, the fa-
vorable safety and efﬁcacy proﬁle of zonisamide
seen in the adjunctive, randomized trials may ac-
tually not reﬂect the maximum potential of this
agent.
In the European trial, there were few patients
with secondary generalization of seizures and in the
US trials the results were not analyzed by seizure
type. The Japanese experience indicates that zon-
isamide is effective for secondary generalization,
thus, it would be instructive to have an analysis of
the randomized data according to seizure type to
conﬁrm this ﬁnding.
The US data demonstrate, in a very elegant fash-
ion, the signiﬁcant reduction in adverse events
when the dose of zonisamide is titrated slowly.
For example, slower titration reduced the inci-
dence of difﬁculty in concentrating from 15 to 3%
and that of somnolence from 39 to 15%. Rarely do
clinicians have the opportunity to see this kind of
compelling data on dose titration, although with
a number of drugs in clinical practice, it appears
advisable to stick to the maxim of ‘‘start low, go
slow.’’ These data conﬁrm that zonisamide is no
exception.
With the Japanese, US, and European data, we
have a large database of safety information, which
provides valuable insights into the incidence of
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various adverse events not only in clinical trials,
but also in real world practice. Nevertheless, clini-
cians must remain continually vigilant–—a low inci-
dence or absence of a particular adverse event in
the context of a clinical trial or in the somewhat
different Japanese population should not make us
complacent.
In summary, although ideally, we still need to
reconﬁrm through randomized trials the role of
zonisamide in monotherapy and different seizure
types, the pivotal trial results and Japanese expe-
rience provide an excellent foundation on which
clinicians in the United States and Europe can build
their knowledge of this drug.
